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Background: Gastric cardia adenocarcinoma (GCA) is one of the major causes of cancer related mortality
worldwide. We aim to provide new understanding in the pathogenesis of GCA through investigations on gene
expression alterations.
Methods: We preformed RNA-Seq for one pair of GCA and matched non-tumor tissues. Differentially expressed
genes (DEGs) and fusion genes were acquired. PCR and gel analysis in additional 14 pairs of samples were
performed to validate the chimeric transcripts.
Results: 1590 up-regulated and 709 down-regulated genes were detected. Functional analysis revealed that these
DEGs were significantly overrepresented in gene ontology items of cell cycle, tumor invasion and proliferation.
Moreover, we firstly discovered 3 fusion genes in GCA, including BMX-ARHGAP, LRP5- LITAF and CBX3-C15orf57.
The chimeric transcript BMX-ARHGAP was validated and recurrently occurred in 4/15 independent tumor tissues.
Conclusions: Our results may provide new understanding of GCA and biomarkers for further therapeutic studies.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_218
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Gastric cancer is the fourth most common malignant
cancer and the second major cause of cancer-related
death [1,2]. It is widely believed that gastric cancer is a
heterogeneous disease with multiple environmental and
genetic etiologies. To date, aberrant gene expression and
epigenetic alterations were identified to be involved in
the pathogenesis of gastric cancer. These abnormal changes
could lead to perturbations in normal cellular homeostasis
and neoplastic transformation of the gastric mucosa
[3]. In particular, disruption in a number of regulatory
signal pathways could create a permissive environment
for carcinogenesis, invasiveness and metastasis. Gastric
adenocarcinoma comprises 95% of the malignant gastric
tumors [4]. It is classified as proximal (originating in the
cardia) and distal (originating distal to the cardia). Differ-
ent from distal adenocarcinomas, incidence of gastric* Correspondence: wangjj9666@163.com
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unless otherwise stated.cardia adenocarcinoma (GCA) has increased significantly
recently [5-7]. In addition, compared with distal adenocar-
cinomas, GCA seems to be more aggressive with deeper
gastric wall invasion and worse prognosis [5,8]. Therefore,
it is necessary to spend more efforts on the investigations
for uncovering the pathogenesis of GCA.
With the rapid development of next generation sequen-
cing (NGS), many cancer-related genes have been identi-
fied. NGS technology makes it possible to comprehensively
illuminate whole map of genetic alteration of cancer. Spe-
cifically, massively parallel RNA-Sequencing (RNA-Seq)
allows identification of entire gene expression and struc-
tural variation in individual samples, and facilitates fully
characterization of cellular transcriptomes. Consequently,
RNA-Seq becomes a revolutionary tool to study transcrip-
tome profiling and measure the expression levels of vari-
ous transcripts and isoforms [9]. Currently, investigations
on GCA by using RNA-seq are still limited.
In this study, we generated comprehensive mRNA pro-
files in a pair of GCA and adjacent non-tumor tissues. We
performed transcriptome-wide, unbiased analyses of thes an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Statistics of the sequenced reads and its mapping status
Sample Total reads Mapped reads Mapping ratio Total base(bp) Mapped base(bp) Coverage(?)
Non-tumor 53611554 44218606 82.48% 5361155400 4421860600 38.63
Tumor 61217124 49477807 80.82% 6121712400 4947780700 43.22
Figure 1 The evenness (left) and integrity (right) of reads distribution. The left two figures show the reads distribution in different parts of
genes. The X-axis represents that the gene body is divided into 100 parts from 5? end to 3? end. The Y-axis represents the number of reads in
different parts. The right two figures show the reads coverage rate distribution in genes. Coverage rate is count by reads covered gene length
divided by total length of the gene.
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Table 3 The differentially alternative splicing events
A3SS A5SS MXE RI SE Total
Tumor vs. Non-tumor (raw) 31 38 53 75 114 311
Tumor vs. Non-tumor (filtered) 5 10 11 12 23 61
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tional aberrations (mRNA expression and chimeric tran-
script) to investigate the molecular mechanism of gastric
cancer pathogenesis. Interesting fusion genes were further
validated in other independent samples. Our results may
provide new understanding of GCA pathogenesis and new
targets for future therapeutic studies.
Methods
Sample information
The GCA tissue and adjacent non-tumor tissue (5 cm
away from tumor) were collected from a 65 years old
male patient who was diagnosed as T4N0M0 stage IIB
GCA in 2012. The tumor size was 5 ? 4 ? 1 cm. The
tumor was moderately differentiated and didn ? t spread
to nearby lymph nodes or other organs. However, both
venous invasion and nerve invasion were positive.
For validation of interesting fusion genes, another 14
pairs of stage IIB GCA and adjacent non-tumor tissues
were obtained with the same procedure. Signed informed
consent documents were obtained from all patients. The
scientific use of these samples was approved by the Insti-
tutional Review Boards of the People? s hospital, Jingjiang,
Jiangsu, China.Table 2 Gene ontology items and pathways that
significantly overrepresented with differentially
expressed genes
ID Description P value
Gene ontology
GO:0022403 cell cycle phase 2.11E-15
GO:0000279 M phase 4.11E-15
GO:0007049 cell cycle 7.68E-14
GO:0000280 nuclear division 1.87E-13
GO:0007067 mitosis 1.87E-13
GO:0048285 organelle fission 4.94E-13
GO:0022402 cell cycle process 5.06E-13
GO:0000087 M phase of mitotic cell cycle 5.06E-13
GO:0000278 mitotic cell cycle 6.84E-11
GO:0051301 cell division 4.74E-10
GO:0042127 regulation of cell proliferation 6.42E-07
GO:0007155 cell adhesion 1.47E-06
GO:0022610 biological adhesion 1.59E-06
GO:0007059 chromosome segregation 1.47E-05
GO:0007051 spindle organization 1.99E-05
GO:0007010 cytoskeleton organization 3.29E-05
KEGG pathway
hsa05130 Pathogenic Escherichia coli infection 9.84E-03
hsa04512 ECM-receptor interaction 1.29E-02
hsa04110 Cell cycle 1.86E-02RNA-Seq library preparation and Illumina sequencing
Total RNA was isolated from frozen tissue by Trizol
(Invotrogen) and its quality was assessed using Agilent
Bioanalyzer. RNA-Seq libraries were prepared by TruSeq
RNA Sample Prep Kit (Illumina Cat. No. FC-122-1001)
according to standard protocols. Then the Libraries were
sequenced on an Illumina Genome Analyzer IIx with
115 bp pair-end read length.
RNA-Seq data processing
For the raw data, low quality reads were filtered according
to the criteria as follows: (1) reads containing adaptors
were filtered; (2) nucleotides with a quality score lower
than 20 were trimmed. The clean reads were aligned
against both genome hg19 and transcripts reference using
Bowtie 2.0.0 [10] and Tophat1.3.1 [11]. The mapping
reads without biological interest, such as ribosomal RNAs
and mitochondrial RNA were removed. The results of
read mapping was visualized by using Integrative Genom-
ics Viewer (IGV 2.0.26) [12].
Detection of differentially expressed genes (DEGs)
To identify DEGs, the values of human genes were nor-
malized by per kilobase of exon per million mapped
reads (FPKM) using Cufflinks (1.0.3) [13]. DEGs between
GCA and non-tumor tissues were determined with signifi-
cance cutoff of q-value <0.05. In addition, gene ontology
(GO) and KEGG pathway enrichment analyses were per-
formed via the web tool DAVID (http://david.abcc.ncifcrf.
gov/) [14] with the false discovery rate (FDR) <0.05.
Alternative splicing event detection
The alternative splicing events were detected by MISO
software [15], including alternative 3 ? splice sites (A3SS),
alternative 5? splice sites (A5SS), mutually exclusive exons
(MXE), retained intron (RI) and skipped exons (SE). Dif-
ferentially expressed isoforms were further identified with
following criteria: 1) the value of gene expression differ-
ence >0.2; 2) Bayes factors >10; 3) inclusive reads >1,Table 4 Summary of candidate fusion genes detected by
RNA-Seq
No. Gene1 Gene2 Break point1 Break point2
1 BMX ARHGAP12 chrX:15548096 chr10:32217611
2 LRP5 LITAF chr11:68125315 chr16:11650591
3 C15orf57 CBX3 chr15:40854974 chr7:26241386
Figure 2 (See legend on next page.)
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Figure 2 Detection and validation of the fusion gene BMX-ARHGAP in gastric cardia adenocarcinoma. A. BMX locates in chromosome X
and ARHGAP locates in chromosome 10. The breakpoint of BMX-ARHGAP is supported by both paired reads and single reads. B. Validation of the
gene fusion with the target band of 260 bp. Sample 10 is the sequencing sample. T and N represent tumor and non-tumor tissue, respectively. It
is obviously the expected target band is present in the tumor tissues of sample 7, 10, 12, and 17.
Table 5 The primer sequences used in PCR and gene
fusion validation






*the control; $primer used to amplify gene fusion.
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sive reads >10.
Fusion gene identification
Fusion gene was identified by Defuse [16] and TopHat
[17]. The filtering processes of Defuse were carried out
as previously described [18]. Fusion genes detected by
TopHat should meet the following criteria: 1) support
reads number should be more than 3; 2) the supporting
reads should not be mapped to ribosomal protein or small
nuclear ribonucleoproteins. Only fusion genes detected by
both methods were remained.
Gene fusion validation
To validate fusion transcripts, we performed PCR and
gel analysis in the sequence sample and another 14 pairs
of GCA and adjacent non-tumor tissues. All patients
were also diagnosed as T4N0M0 stage IIB GCA. Primer
pairs were designed using Primer 5 software, and RT-
PCR was performed using the following procedure: 94?C
for 1 min, 40 cycles of 94?C for 20 sec, 55?C for 20 sec
and 72?C for 15 sec, followed by 72?C for 1 min. The
PCR products of the fusion genes were visualized
through agarose gel electrophoresis.
Results
In order to explore the spectrum of gene transcriptional
changes in GCA, we sequenced the whole gene tran-
scripts in one pair of GCA and matched non-tumor
tissues from a 65 years old patient. We generated a total
of 5.36 and 6.12 Gb data for the tumor and non-tumor
tissue, respectively. Approximately 80% reads were mapped
to the reference genome, achieving an average depth of
coverage of 38.63 X and 43.32 X, respectively (Table 1).
The sequencing reads achieved fairly well evenness and
integrity (Figure 1).
Next we analyzed gene expression level via calculating
FPKM using the Cufflinks. About 15 thousand genes
were expressed (FPKM >1) in our samples, among which
1590 genes were up-regulated and 709 genes were
down-regulated in tumor. According to the enrichment
analysis, these DEGs were significant overrepresented in
16 GO terms and 3 pathways, which were related to cell
cycle, tumor invasion and proliferation (Table 2).
Alternative splicing events were also detected by using
MISO. We found 311 differentially alternative spliced
events. After the filtering process, 61 alternative splicingevents were remained according to Bayes factors, Psi
values and confidence intervals (Table 3).
Many fusion genes were reported as the potential cause
for tumorigenesis, including gastric cancer [19,20]. Using
Defuse and TopHat, 7 candidate fusion genes were identi-
fied with stringent filtering criteria. And finally 3 fusion
genes were selected by TopHat realignment and manual
inspection (Table 4, Figure 2). The fusion gene BMX-
ARHGAP was validated using RT-PCR and gel analysis
(Table 5), which was recurrently present in tumor tissues
in about 26.7% (4/15) GCA patients (Figure 2).
Discussion
The development of cancer is a multistep process during
which cells acquires a series of mutations that eventually
lead to unrestrained cell growth and division, inhibition
of cell differentiation, and evasion of cell death. In order
to comprehensively study aberrant gene expression in
GCA, we performed the current study by using paired-end
RNA-Seq technology. The results revealed the information
of DEGs, alternative splicing, and gene fusion, which may
have potential application in therapeutic studies.
In the present study, over 400 M reads were sequenced
on the Illumina platform, reaching about 40 X coverage
for the whole transcriptome. With those high sequencing
depth, 2299 DEGs were detected between GCA and non-
tumor tissue. Further analysis showed ECM and cell cycle
were the most enriched biological pathway among those
abnormal expressed genes.
Alternative splicing is an important regulatory process
during gene expression and substantially results in diverse
transcripts. Abnormally spliced mRNAs were also found
in multiple cancerous cells, including gastric cancer, breast
cancer, and colon cancer [21,22]. In our study, 61 alterna-
tive spliced events were identified by using MISO soft-
ware. Among them, CD44 was also found be abnormally
spliced in colorectal cancer and was suggested to be the
character of metastatically potent tumor cells [23].
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involved in the development of various types of malignan-
cies including leukemia, lymphoma, breast and prostate
cancer [24]. Importantly, several fusion genes, DUS4L?
BCAP29 [19], CD44-SLC1A2 [20] have been reported in
gastric cancer in western country. In our study, 3 chimeric
transcripts were supported by the two detection methods
(Table 4). Among them, CBX3-C15orf57 was detected in
healthy human beings before [25]. In addition, both CBX3
and C15orf57 were recurrently partnered with others in
breast cancer [26]. Our results implicate the potential
involvement of CBX3-C15orf57 in GCA. BMX-ARHGAP12
was firstly validated and was detected recurrently in 4 out
of 15 GCA patients (Figure 2). BMX encodes a non-
receptor tyrosine kinase and ARHGAP12 encodes a Rho
GTPase activating protein. It is possible that the chimeric
transcript active the BMX mediation of tumorigenicity in
GCA patients since BMX has been suggested to promote
tumor growth and metastasis other cancers [27,28]. In
addition, overexpression of ARHGAP12 would impair cell
scattering, invasion and adhesion to fibronectin [29]. This
fusion gene may play important roles in the tumorigenesis
and may be potential targets for novel therapeutic strategy.
Conclusions
In summary, we performed transcriptome-wide analysis
to identify gene expression aberrations in GCA. One of
identified fusion gene, BMX-ARHGAP12, was further
confirmed in another independent patient. Our results
may provide new understanding of the pathogenesis and
new targets for further therapeutic investigations.
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